We are live on ! Find out more
ZVRA icon

Zevra Therapeutics

93 hedge funds and large institutions have $78.6M invested in Zevra Therapeutics in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more capital inflows, than outflows

Capital inflows: $12.6M | Capital outflows: $3.54M

228% more call options, than puts

Call options by funds: $985K | Put options by funds: $300K

167% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 15

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

4% more funds holding

Funds holding: 89 → 93 (+4)

4.05% more ownership

Funds ownership: 34.29% → 38.33% (+4%)

Holders
93
Holders Change
+4
Holders Change %
+4.49%
% of All Funds
1.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
40
Reduced
15
Closed
10
Calls
$985​K
Puts
$300​K
Net Calls
+$685​K
Net Calls Change
+$424​K

ZVRA Hedge Fund Activity: Q2 2024 in Review

93 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2024, worth a combined $78.6M — down 2.6% from $80.7M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ZVRA positions and 10 closed out — a net gain of 2 holders — while 40 added to existing stakes and 15 trimmed.

The largest buyer was Altium Capital Management, adding an estimated $3.89M. The largest seller was Janney Montgomery Scott, cutting an estimated $1.08M.

  • 93 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2024, up from 89 in Q1 2024.
  • Funds reported $78.6M of Zevra Therapeutics stock for Q2 2024, down 2.6% quarter-over-quarter.
  • 12 funds opened new Zevra Therapeutics positions in Q2 2024 and 10 closed out, a net change of +2 holders.
  • The largest Zevra Therapeutics buyer in Q2 2024 was Altium Capital Management, an estimated $3.89M added.
  • The largest Zevra Therapeutics seller in Q2 2024 was Janney Montgomery Scott, an estimated $1.08M sold.

Based on aggregated 13F filings for Q2 2024.